Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;9(2):78-81.
doi: 10.1016/j.prnil.2020.10.001. Epub 2020 Oct 17.

Rebiopsy rate after transperineal or transrectal prostate biopsy

Jose L Marenco Jimenez  1 , Francesco Claps  1   2 , Juan C Ramón-Borja  1 , Juan M Mascarós Martinez  1 , Augusto W Gutierrez  1 , Álvaro G F Lozano  1 , Miguel Ramírez-Backhaus  1 , Jose L Domìnguez Escrig  1 , Argimiro C Serra  1 , Jose Rubio-Briones  1
Affiliations

Rebiopsy rate after transperineal or transrectal prostate biopsy

Jose L Marenco Jimenez et al. Prostate Int. 2021 Jun.

Abstract

Background: In recent years, transperineal biopsies gained popularity for prostate cancer diagnosis; lower infective complications and improved sampling of the prostate are the main advantages of this technique. One question that remains unclear is whether an initial transperineal biopsy confers a lower risk for rebiopsy compared with the transrectal approach.

Methods: Six hundred seventy-one men were prospectively followed after an initial negative prostate biopsy for a median period of 49.50 (IQR: 37.62-61.17) months. Rebiopsy rate was analyzed attending to first biopsy approach (transrectal versus transperineal systematic) and clinical variables.

Results: Diagnostic rate was similar for transrectal and transperineal systematic biopsies. Targeted biopsies outperformed any systematic approach, and transperineal targeted in particular was superior to transrectal targeted. Rebiopsy rates were 15.4% and 5.26% for the transrectal and transperineal systematic groups, respectively. Prostate-specific antigen density and type of first biopsy were identified as rebiopsy predictors.

Conclusion: Men undergoing transperineal systematic biopsies had a three times lower rate of rebiopsy over the study period compared with the traditional transrectal approach. This advantage could be added to the already described potential benefits of transperineal biopsies. Targeted biopsies had lower rebiopsy rate over the study period. Further innovations that decreased the cost of transperineal biopsies could favor this approach in the future.

Keywords: Prostate biopsy; Prostate cancer; Prostate cancer diagnosis; Transperineal biopsy; Transrectal biopsy.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflict of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mottet N., van den Bergh R.C.N., Briers E., Cornford P., De Santis M., Fanti S. 2019. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. - PubMed
    1. Loeb S., Carter H.B., Berndt S.I., Ricker W., Schaeffer E.M. Complications after prostate biopsy: Data from SEER-Medicare. J Urol. 2011;186(5):1830–1834. doi: 10.1016/j.juro.2011.06.057. Available from. - DOI - PMC - PubMed
    1. Skouteris V.M., Crawford E.D., Mouraviev V., Arangua P., Metsinis M.P., Skouteris M. Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison. Rev Urol. 2018;20(1):19–25. - PMC - PubMed
    1. Abdulmajed M.I., Hughes D., Shergill I.S. The role of transperineal template biopsies of the prostate in the diagnosis of prostate cancer: A review. Exp Rev Med Dev. 2015;vol. 12:175–182. Expert Reviews Ltd. - PubMed
    1. Merrick G.S., Gutman S., Andreini H., Taubenslag W., Lindert D.L., Curtis R. Prostate Cancer Distribution in Patients Diagnosed by Transperineal Template-Guided Saturation. Biopsy. 2007;52:715–724. - PubMed